Nyxoah Aktie
WKN DE: A2QCWK / ISIN: BE0974358906
18.11.2024 22:30:00
|
Publication relating to transparency notifications
REGULATED INFORMATION
Publication relating to transparency notifications
Mont-Saint-Guibert (Belgium), November 18, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.
On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold. Based on the notification, ResMed Inc. holds 1,727,864 voting rights, representing 4.62% of the total number of voting rights on October 9, 2024 (37,389,015).
The notification dated November 5, 2024 contains the following information:
- Reason for the notification: passive crossing of a threshold
- Notification by: a person that notifies alone
- Persons subject to the notification requirement:
- ResMed Inc. (with address at 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA)
- Date on which the threshold was crossed: October 9, 2024
- Threshold that is crossed: 5%
- Denominator: 37,389,015
- Notified details:
A) Voting rights | Previous notification | After the transaction | |||
| # of voting rights | # of voting rights | % of voting rights | ||
Holders of voting rights |
| Linked to securities | Not linked to the securities | Linked to securities | Not linked to the securities |
ResMed Inc. | 1,619,756 | 1,727,864 |
|
|
|
| TOTAL | 1,727,864 | 0 | 4.62% | 0.00% |
- Full chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.
*
* *
Contact:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Attachment


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nyxoah S.A. Registered Shsmehr Nachrichten
26.03.25 |
EQS-News: Nyxoah erhält Approvable Letter für sein Genio®-System von der FDA (EQS Group) | |
26.03.25 |
EQS-News: FDA Issues Nyxoah an Approvable Letter for its Genio® System (EQS Group) | |
13.03.25 |
EQS-News: Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results (EQS Group) | |
13.03.25 |
EQS-News: Nyxoah gibt Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 bekannt und informiert über die Unternehmensentwicklung (EQS Group) | |
12.03.25 |
Ausblick: Nyxoah vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
26.02.25 |
Erste Schätzungen: Nyxoah gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
19.02.25 |
EQS-News: Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East (EQS Group) | |
19.02.25 |
EQS-News: Nyxoah gibt die Markteinführung der innovativen Genio®-Therapie im Nahen Osten bekannt (EQS Group) |
Analysen zu Nyxoah S.A. Registered Shsmehr Analysen
Aktien in diesem Artikel
Nyxoah S.A. Registered Shs | 5,90 | 9,26% |
|